No Data
Hong Kong stock movement | ALPHAMAB-B (09966) fell over 14% in the morning session as the company was removed from the Hong Kong Stock Connect list, previously expected to achieve annual profitability for the first time.
ALPHAMAB-B (09966) fell over 14% in early trading, as of the time of writing, it has dropped 12.85%, priced at 5.29 HKD, with a transaction value of 17.1259 million HKD.
ALPHAMAB-B (09966.HK) plans to hold a Board of Directors meeting on March 25 to approve the annual performance.
Gelonghui reported on March 6 that ALPHAMAB-B (09966.HK) announced that the Board of Directors will hold a meeting on Tuesday, March 25, 2025, to consider and approve the annual performance and its announcement of the company and its subsidiaries for the year ended December 31, 2024, as well as address Other matters.
ALPHAMAB-B: DATE OF BOARD MEETING
[Company profit alert] Corning Jereh Pharmaceutical (09966) expects to turn a profit in 2024 with a year-on-year increase to not less than 0.15 billion yuan.
Jingwu Financial News | Corning Jereh Pharmaceutical (09966) announced that the group expects to record a profit of no less than 0.15 billion yuan for the year ending December 31, 2024, while a loss of approximately 0.211 billion yuan was recorded for the year ending December 31, 2023. This marks the company's first annual profit.
Hong Kong stock morning report | The USA fires the first shot in a comprehensive trade war, the three major US stock indices fall while Chinese concept stocks rise against the trend.
① The USA's tariff measures against Mexico and Canada officially took effect on Tuesday, after which both Canada and Mexico launched a comprehensive counterattack. The US Secretary of Commerce stated that Trump is considering reducing some tariffs on Mexico and Canada. ② China has continuously introduced countermeasures against the USA. ③ Zelensky stated he is ready to sign agreements with the USA regarding minerals and security at any time. ④ The three major US stock indexes fell on Tuesday, while most China Concept Stocks rose against the trend.
ALPHAMAB-B (09966.HK) expects to turn a loss into a profit of over 0.15 billion yuan for the year.
On March 4, Gelonghui reported that ALPHAMAB-B (09966.HK) announced that the company expects to record a profit of not less than 150 million yuan for the year ending December 31, 2024, while a loss of approximately 210.6 million yuan was recorded for the year ending December 31, 2023. This marks the company's first annual profit. The turnaround from loss to profit during the reporting period is mainly due to three authorized partnerships and sales revenue.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
